Tardive Dyskinesia Pipeline Summary

DelveInsight’s, “Tardive Dyskinesia - Pipeline Insight, 2026” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Tardive Dyskinesia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Tardive Dyskinesia: Understanding

Tardive Dyskinesia: Overview

Tardive dyskinesia (TD) is a persistent, involuntary hyperkinetic movement disorder that typically develops after prolonged exposure to dopamine receptor-blocking agents, particularly antipsychotic medications. It is considered a form of tardive syndrome and can occur with both first- and second-generation antipsychotics, although risk is generally higher with prolonged exposure to first-generation agents. TD may persist even after the causative medication is reduced or discontinued and can significantly impair physical functioning, social interactions and quality of life.

TD most commonly presents with repetitive, involuntary movements of the mouth, tongue, jaw and face, including lip smacking, chewing, tongue protrusion, grimacing and rapid blinking. Movements may also involve the trunk and limbs and can include choreiform movements, dystonia, tremor or abnormal gait; in some patients, respiratory or swallowing muscles may be affected. Symptoms can fluctuate in severity and may become more apparent during voluntary movement or emotional stress. Severe TD can interfere with speaking, eating, walking and other daily activities.

The primary cause of TD is chronic exposure to dopamine receptor-blocking agents, including antipsychotics and certain antiemetic or gastrointestinal medications. Its pathophysiology is not completely understood, but prolonged dopamine D2-receptor blockade is thought to produce compensatory receptor upregulation and dopamine hypersensitivity within the striatum. Additional mechanisms may include oxidative stress, impaired GABAergic signaling, altered synaptic plasticity and neuroadaptive changes in basal-ganglia circuits. Older age, longer cumulative drug exposure and certain psychiatric or metabolic comorbidities can increase susceptibility.

Diagnosis is primarily clinical, based on the characteristic involuntary movements, medication history and exclusion of other movement disorders; the Abnormal Involuntary Movement Scale (AIMS) is commonly used to screen and monitor severity over time. Management begins with prevention and, where clinically appropriate, reducing the dose of the offending dopamine receptor-blocking drug or switching to an alternative with lower TD risk. For persistent or clinically significant TD, VMAT2 inhibitors such as valbenazine and deutetrabenazine are established pharmacological treatments, while clozapine, botulinum toxin for selected focal manifestations and other specialist interventions may be considered in appropriate patients.

"Tardive Dyskinesia- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tardive Dyskinesia pipeline landscape is provided which includes the disease overview and Tardive Dyskinesia treatment guidelines. The assessment part of the report embraces, in depth Tardive Dyskinesia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology,

Tardive Dyskinesia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Tardive Dyskinesia R&D. The therapies under development are focused on novel approaches to treat/improve Tardive Dyskinesia.

Tardive Dyskinesia Emerging Drugs Chapters

This segment of the Tardive Dyskinesia report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Tardive Dyskinesia Emerging Drugs

NBI-1065890: Neurocrine Biosciences

NBI-1065890 is an investigational oral next-generation, selective vesicular monoamine transporter 2 (VMAT2) inhibitor being developed by Neurocrine Biosciences for tardive dyskinesia (TD). By inhibiting VMAT2, it is designed to modulate presynaptic dopamine storage and release, thereby reducing excessive dopaminergic signaling associated with involuntary movements in TD. NBI-1065890 entered a Phase II clinical study in adults with TD, with the program intended to evaluate its efficacy, safety and tolerability as a potential treatment for the disorder. The trial is a Phase II, randomized, double-blind, placebo-controlled study sponsored by Neurocrine Biosciences to evaluate the efficacy, safety, and tolerability of the investigational VMAT2 inhibitor in adults with tardive dyskinesia. The primary endpoint is the change from baseline in the AIMS dyskinesia total score (Items 1–7) at Week 8, assessed by blinded central video raters. A key secondary endpoint is the proportion of participants achieving a response on the Clinical Global Impression–Improvement (CGI-I) scale at Week 8.

Further product details are provided in the report……..

Tardive Dyskinesia: Therapeutic Assessment

This segment of the report provides insights about the different Tardive Dyskinesia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Tardive Dyskinesia
• There are approx. 4+ key companies which are developing the therapies for Tardive Dyskinesia. The companies which have their Tardive Dyskinesia drug candidates in the mid stage, i.e. Phase II include, Neurocrine Biosciences.

• Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Tardive Dyskinesia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Tardive Dyskinesia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Tardive Dyskinesia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tardive Dyskinesia drugs.

Tardive Dyskinesia Report Insights

• Tardive Dyskinesia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Tardive Dyskinesia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Tardive Dyskinesia drugs?
• How many Tardive Dyskinesia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tardive Dyskinesia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Tardive Dyskinesia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Tardive Dyskinesia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Neurocrine Biosciences
• Serina Therapeutics, Inc.

Key Products

• NBI-1065890
• SER-270